These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
620 related articles for article (PubMed ID: 29759659)
1. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Nolte H; Maloney J Allergol Int; 2018 Jul; 67(3):301-308. PubMed ID: 29759659 [TBL] [Abstract][Full Text] [Related]
2. Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma. Brunton S; Nelson HS; Bernstein DI; Lawton S; Lu S; Nolte H Postgrad Med; 2017 Aug; 129(6):581-589. PubMed ID: 28326908 [TBL] [Abstract][Full Text] [Related]
3. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis. Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533 [TBL] [Abstract][Full Text] [Related]
5. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses. Durham SR; Creticos PS; Nelson HS; Li Z; Kaur A; Meltzer EO; Nolte H J Allergy Clin Immunol; 2016 Oct; 138(4):1081-1088.e4. PubMed ID: 27527264 [TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
7. Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis. Devillier P; Wahn U; Zielen S; Heinrich J Expert Rev Clin Immunol; 2017 Dec; 13(12):1199-1206. PubMed ID: 29072507 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma. Hesse L; Nawijn MC Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043 [TBL] [Abstract][Full Text] [Related]
9. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study. Contoli M; Porsbjerg C; Buchs S; Larsen JR; Freemantle N; Fritzsching B J Allergy Clin Immunol; 2023 Aug; 152(2):445-452.e4. PubMed ID: 36871918 [TBL] [Abstract][Full Text] [Related]
10. State of the Art: Development of a Sublingual Allergy Immunotherapy Tablet for Allergic Rhinitis in Japan. Ohashi-Doi K; Lund K; Mitobe Y; Okamiya K Biol Pharm Bull; 2020; 43(1):41-48. PubMed ID: 31902930 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir. Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA Front Immunol; 2021; 12():723814. PubMed ID: 34721385 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719 [TBL] [Abstract][Full Text] [Related]
13. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977 [TBL] [Abstract][Full Text] [Related]
14. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. Mösges R; Ritter B; Kayoko G; Allekotte S Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414 [TBL] [Abstract][Full Text] [Related]
15. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets. Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323 [TBL] [Abstract][Full Text] [Related]
16. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268 [TBL] [Abstract][Full Text] [Related]